Pfizer Exceeds Q2 Estimates, Raises Revenue Forecast on Non-Covid Products
Pfizer adjusts full-year Covid product revenue expectations downward but boosts overall guidance fueled by non-Covid product strength.
On August 4, 2026, Pfizer reported second-quarter earnings that surpassed analysts' expectations. While the pharmaceutical company lowered its full-year revenue forecast for Covid-19 related products to $4 billion, down from a previous estimate of approximately $5 billion, it raised the lower end of its total revenue guidance. This upward revision was attributed to stronger performance in non-Covid products.
Sources
CNBC — Pfizer tops quarterly estimates, hikes low end of revenue guidance on strength of non-Covid productsTHE QUESTIONS THIS EVENT LEAVES BEHIND